Determination of high-density lipoproteins: screening methods compared.

Gerhard M. Kostner, P Avogaro, Giulia Bon, +2

Clinical Chemistry

Lipid AnalysisDextran SulfateHyperlipidemiaMetabolic SyndromeVenetian Screening Program +14

Resensitization of breast cancer cells to anoikis by Tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion

Shantaram Bharadwaj, Ruchi Thanawala, Giulia Bon, +2

Oncogene

Rho Kinase-dependent CytoskeletonCell AdhesionBreast Cancer CellsCell-matrix InteractionCell Migration +10

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells

Rossella Loria, Giulia Bon, Valentina Perotti, +11

Oncotarget

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Giulia Bon, Laura Pizzuti, Valentina Laquintana, +48

Journal of Experimental & Clinical Cancer Research

Purification and Characterization of Adipose-Derived Stem Cells from Patients with Lipoaspirate Transplant

Valentina Folgiero, Emilia Migliano, M Tedesco, +7

Cell Transplantation

Tissue EngineeringEngineeringAdult Stem CellTissue TransplantationBiomedical Engineering +18

The α6β4 Integrin Can Regulate ErbB-3 Expression: Implications for α6β4 Signaling and Function

Valentina Folgiero, Robin E. Bachelder, Giulia Bon, +3

Cancer Research

Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression.

Giulia Bon, Valentina Folgiero, Selene E. Di Carlo, +2

Breast Cancer Research

Alpha6beta4 IntegrinBreast OncologyMedicineCell-matrix InteractionBreast Cancer +6

Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas

Valentina Folgiero, Paolo Avetrani, Giulia Bon, +12

PLoS ONE

Negative Regulation of β4 Integrin Transcription by Homeodomain-Interacting Protein Kinase 2 and p53 Impairs Tumor Progression

Giulia Bon, Selene E. Di Carlo, Valentina Folgiero, +9

Cancer Research

Cancer BiologyTumor BiologyMutant P53P53 FunctionSignaling Pathway +18

miR-221/222 control luminal breast cancer tumor progression by regulating different targets

Patrizia Dentelli, Matteo Traversa, Arturo Rosso, +10

Cell Cycle